Evidence map›Paper›PMID 19471212›Full record

ArticleMolecules (Basel, Switzerland)2009

New macrocyclic amines showing activity as HIV entry inhibitors against wild type and multi-drug resistant viruses.

Stefano Rusconi, Mirko Lo Cicero, Ottavia Viganò, Francesca Sirianni, Elisabetta Bulgheroni, Stefania Ferramosca, Andrea Bencini, Antonio Bianchi, Lidia Ruiz, Cecilia Cabrera and 3 more

Abstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Stefano RusconiDipartimento di Scienze Cliniche Luigi Sacco, Sezione di Malattie Infettive e Immunopatologia, Università degli Studi, Ospedale Luigi Sacco, Milano, Italy. stefano.rusconi@unimi.it
Mirko Lo Cicero
Ottavia Viganò
Francesca Sirianni
Elisabetta Bulgheroni
Stefania Ferramosca
Andrea Bencini
Antonio Bianchi
Lidia Ruiz
Cecilia Cabrera
Javier Martinez-Picado
Claudiu T Supuran
Massimo Galli

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Considering as a lead molecule the chemokine CXCR4 receptor antagonist AMD-3100, which shows significant anti-HIV activity in vitro and in vivo, we investigated a series of structurally related macrocyclic polyamines incorporating o,o'-phenanthroline or 2,2'-bipyridyl scaffolds as potential antiviral agents with lower toxicity and increased activity against both wild type X4-tropic and dual tropic HIV strains. The antiviral activity of these compounds was evaluated by susceptibility assays in PBMC (Peripheral Blood Mononuclear Cells) and compared to that of AMD-3100. The newly investigated compounds showed IC(50)s values in the low micromolar range and significantly inhibited the viral replication of wild type X4-tropic isolate and dual tropic strains. These macrocyclic polyamines constitute a promising class of HIV entry inhibitors.

Indexed as

Drug Resistance, MultipleDrug Resistance, ViralAminesAnti-HIV AgentsBenzylaminesCyclamsHeterocyclic CompoundsHIV-1HIV Fusion InhibitorsHIV InfectionsHumansMolecular StructurePhenotypePolyaminesReceptors, CXCR4AminesAnti-HIV AgentsBenzylaminesCyclamsHeterocyclic CompoundsHIV Fusion InhibitorsplerixaforPolyaminesReceptors, CXCR4

Identifiers

PMID19471212
PMCPMC6254439

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.